Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary

Shubow, Sophie; Sun, Qin; Phan, Ai Len Nguyen; Hammell, Dana C.; Kane, Maria; Lyman, Gary H.; Gibofsky, Allan; Lichtenstein, Gary R.; Bloomgarden, Zachary T.; Cross, Raymond K.; Yim, Sarah; Polli, James E.; Wang, Yow‐Ming

doi:10.1002/cpt.2765

Cited by 4 publications

(3 citation statements)

References 53 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42, 43 A knowledge gap among providers may be another issue, as familiarity and terminology could play a role in choosing the agent. 44, 45 It should be emphasized that projecting savings associated with biosimilars entrance on the United States market depends on changing regulatory structure and insurer's calculations. [46][47][48] Policy changes toward extending access to innovative treatment should also consider patient--level factors, with potential preference for oral or subcutaneous formulations.…”

Section: Discussionmentioning

confidence: 99%

Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study

Stajszczyk,

Kwiatkowska,

Żuber

et al. 2024

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Biologics and JAK inhibitors in rheumatic diseases in Poland 1 the possibility to improve quality of life through goal -directed therapy. 6,7 High effectiveness of biologic drugs, marked by a remarkable reduction of inflammatory symptoms, limited disease progression, including joint damage, and improved physical function, makes them a pillar of standard therapies. The steroid sparing effect and avoiding complications associated with chronic steroid use are the other important benefits for the patients. 6 However, a high degree of clinical and immunologic variability is observed within all major arthritides, which translates into different patient INTROduCTION Rheumatic musculoskeletal diseases (RMDs), including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), represent a major challenge from a socioeconomic and health care perspective. 1-3 Timely diagnosis, stringent disease control, and effective treatment are crucial steps in preventing disease -related disability. Access to synthetic and biologic disease-modifying antirheumatic drugs (bDMARDs) has changed a natural course of inflammatory arthritis, 4 including extra -articular manifestations, 5 and has extended

show abstract

Section: Discussionmentioning

confidence: 99%

Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study

Stajszczyk,

Kwiatkowska,

Żuber

et al. 2024

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Three articles in this issue discuss efforts needed to improve biosimilar uptake and adoption. Shubow et al 16 . describe the perspectives of four leading academic clinicians with specialties in oncology, rheumatology, gastroenterology, and endocrinology, which was informed by their clinical experience and real‐world data on clinical use of biosimilars globally.…”

Section: Improving Biosimilar Uptake and Adoptionmentioning

confidence: 99%

“…Three articles in this issue discuss efforts needed to improve biosimilar uptake and adoption. Shubow et al 16 perspectives of four leading academic clinicians with specialties in oncology, rheumatology, gastroenterology, and endocrinology, which was informed by their clinical experience and real-world data on clinical use of biosimilars globally. They call for educational efforts to highlight the rigor of studies that support the of biosimilarsincluding the clinical pharmacology studies-and the benefits of biosimilars, thereby increasing the awareness, building the confidence, and ultimately improving biosimilar acceptance.…”

Section: Improving Biosimilar Uptake and Adoptionmentioning

confidence: 99%

Advancing Innovations in Biosimilars

Wang

Strauss

2022

Clin Pharma and Therapeutics

Self Cite

View full text Add to dashboard Cite

Optimising oncology drug expenditure in Ireland

Kieran,

Hennessy,

Coakley

et al. 2024

Ir J Med Sci

View full text Add to dashboard Cite

A combination of improvements in patient survival, increasing treatment duration, and the development of more expensive agents has led to a doubling of per-capita spending on cancer medicines in Ireland (2008–2018). Despite this, access to new drugs is poor in comparison to other EU countries. We examine methods to optimise oncology drug spending to facilitate access to newer anticancer agents. Key targets for spending optimisation (biosimilar use, clinical trials and expanded access programs, waste reduction, avoidance of futile treatment, and altered drug scheduling) were identified through an exploratory analysis. A structured literature search was performed, with a focus on articles relevant to the Irish Healthcare system, supplemented by reports from statutory bodies. At the present time, EMA-approved agents are available once approved by the NCPE. Optimising drug costs occurs through guideline-based practice and biosimilar integration, the latter provides €80 million in cost savings annually. Access to novel therapies can occur via over 50 clinical trials and 28 currently available expanded access programmes. Additional strategies include reversion to weight-based immunotherapy dosing, potentially saving €400,000 per year in our centre alone, vial sharing, and optimisation of treatment schedules. A variety of techniques are being employed by oncologists to optimise costs and increase access to innovation for patients. Use of biosimilars, drug wastage, and prescribing at end of life should be audited as key performance indicators, which may lead to reflective practice on treatment planning. Such measures could further optimise oncology drug expenditure nationally facilitating approval of new agents.

show abstract

Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary

Cited by 4 publications

References 53 publications

Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study

Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study

Advancing Innovations in Biosimilars

Optimising oncology drug expenditure in Ireland

Contact Info

Product

Resources

About